Innovative Use of Computational Biology Unveils Several Drugs Prescribed for Other Diseases May Benefit Select AML Patients
(Atlanta, GA,) December 11, 2017 -- Cellworks Group, Inc. and CancerPOP, LLC today announced data at the American Society of Hematology 2017 Annual Meeting from multiple studies using computational biology to study acute myeloid leukemia (AML). The studies used highly complex genetic and chromosome mutations to build computer digital models of AML patients. The results found that some AML patients may benefit from drugs that are currently indicated for and typically prescribed for other diseases
Digital drug simulations identified the following investigational drugs with high efficacy in reducing AML cell growth: AGI-5198 (IDH1 inhibitor), AGI-6780 (IDH2 inhibitor) and JQ1 (BET inhibitor). The computational programming was also used to digitally screen for already FDA approved drugs with potential activity in AML. The drugs identified by the screening included: venetoclax (approved for the treatment of chronic lymphocytic leukemia), palbociclib (approved for the treatment of breast cancer), and ruxolitinib (approved for the treatment of myelofibrosis).
“Computers can be used to interpret genetic mutations in leukemia and help us move forward in finding new options for AML patients,” said Christopher R. Cogle, M.D., professor at the University of Florida and Chief Executive Officer of CancerPOP. “Results from these studies will lead to precision oncology clinical trials where we match patients, based on their cancer genetics, to these new drug combinations,” he added
”Next generation sequencing has the ability to generate large quantum of tumor data for each patient, but the majority of that information cannot be used,” said Yatin Mundkur, CEO of Cellworks Group Inc. “Computer modeling of patients allows us to predict responses to standard-of-care agents and also identify other therapeutic solutions with mechanistic insight for clinicians to decide on the right treatment for the patient at a given point in time.”
“AML is a genetically heterogeneous disease, such that no two patients are alike,” said Jeffrey Tyner, Ph.D., Associate Professor at Oregon Health & Science University and co-Director of the Leukemia & Lymphoma Society Beat AML Research Network. “Discovering new treatment options for AML patients is exactly what we envisioned when we created the Beat AML Network.”
The abstracts presented include:
Abstract #2707; Poster; Sunday, December 10, 6:00 PM, Building A, Level 1, Hall A2. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Drug Sensitivity Testing (Drusbosky, et al)
Abstract #3907; Poster; Monday, December 11, 6:00 PM, Building A, Level 1, Hall A2. Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study (Drusbosky, et al)
Abstract #3908; Poster; Monday, December 11, 6:00 PM, Building A, Level 1, Hall A2. Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study (Drusbosky, et al)
Abstract #3909; Poster; Monday, December 11, 6:00 PM, Building A, Level 1, Hall A2. Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study (Drusbosky, et al)
About Cellworks Group
Cellworks is a leader in Precision Medicine and the global pioneer of Therapeutic Responder Identification (TRI) technology. Using breakthrough modeling, simulation and AI techniques, TRI is advancing the application of Precision Medicine by providing clinicians with insight into which therapy will prove effective for a specific patient, and providing biopharma companies with tools to select clinical trial cohorts. TRI has the potential to transform lives by early adoption of successful therapies and accelerated availability of new drugs, while at the same time saving time and cost across the healthcare ecosystem. For more information, visit http://www.cellworks.life.
CancerPOP is a global personalized medicine company that performs genetic testing and precision oncology consulting for cancer patients and their doctors. For more information, please visit http://www.cancerpop.com. Follow CancerPOP on Social Media: @PrecisionOncologyProgram, @OncologyProgram, and LinkedIn.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Cellworks and CancerPOP bear no responsibility for the security or content of external websites.
Source: Cellworks Group, Inc. and CancerPOP, LLC